Genen­tech vet Troy Cox named Foun­da­tion Med CEO; Mo­men­ta inks a $600M col­lab­o­ra­tion deal

• Troy Cox, the se­nior VP of on­col­o­gy sales and mar­ket­ing at Genen­tech, is leav­ing the big Roche sub­sidiary to take the CEO’s job at Foun­da­tion Med­i­cine $FMI. Long­time CEO Michael Pelli­ni is tak­ing the chair­man’s post as Alex­is Borisy stays on the board.

• Mo­men­ta Phar­ma­ceu­ti­cals $MN­TA is part­ner­ing with Aus­tralia’s CSL on the de­vel­op­ment and com­mer­cial­iza­tion of Fc mul­ti­mer pro­teins, in­clud­ing Mo­men­ta’s M230. Mo­men­ta gets $50 mil­lion up front and a shot at up to $550 mil­lion in mile­stones. “This col­lab­o­ra­tion and li­cense agree­ment with CSL val­i­dates our be­lief that M230 is an ex­cit­ing re­com­bi­nant prod­uct can­di­date for po­ten­tial use in au­toim­mune in­di­ca­tions. It was de­vel­oped us­ing our pro­pri­etary Fc bi­ol­o­gy plat­form and un­der­stand­ing of how in­tra­venous im­munoglob­u­lin (IVIg) works in au­toim­mune dis­eases,” said Mo­men­ta CEO Craig A. Wheel­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.